Lipids and ASCVD

What are the two sources of lipids?

• exogenous

• endogenous

• indigenous

• cytoplasmic

Endogenous lipids are produced in what part of the body?

• kidneys

• heart

• liver

• gall bladder

Defined as acute coronary syndromes, a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin.

• Atherosclerosis

• Cardiometabolic syndrome

• Atherosclerotic Cardiovascular Disease

• Dyslipidemia

Defined as chronic, progressive disease characterized by the accumulation of fatty and fibrous material in the innermost layer of arteries that results in the formation of atherosclerotic plaques.

• Hyperlipidemia

• Myocardial infarction

• Atherosclerosis

• Heart Failure

What transports lipids into the tissues?

• lipoproteins

• Apolipoproteins

• chylomicrons

• VLDL

What is the most abundant atherogenic lipoprotein?

• Chylomicron

• VLDL

• IDL

• LDL

Long term exposure to LDL-C is a key predictor of ASCVD risk.

• True

• False

Reducing LDL-C can slow the progression of plaque volume but does not regress plaque volume.

• True

• False

In individuals without established ASCVD but at high risk of an ASCVD event, low or moderate risk factor modification is a priority

• True

• False

What is the indication of Sybrava?

• Adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia

• For NYHA Class II - IV adult patients

• Adults with controlled LDL-C